Receive our newsletter – data, insights and analysis delivered to you
June 28, 2009

Inotek Sees Positive Results for Glaucoma Drug Study

Inotek Pharmaceuticals has reported positive results for its INO-8875 glaucoma treatment. The results of a Phase I/II randomised, double-blind, placebo-controlled clinical trial of INO-8875 showed that treatment was well tolerated and resulted in a statistically significant reduction in

By cms admin

Inotek Pharmaceuticals has reported positive results for its INO-8875 glaucoma treatment.

The results of a Phase I/II randomised, double-blind, placebo-controlled clinical trial of INO-8875 showed that treatment was well tolerated and resulted in a statistically significant reduction in intraocular pressure (IOP).

The Phase I/II single ascending dose study, involved 84 subjects with primary open-angle glaucoma or ocular hypertension.

Inotek President and CEO Paul Howes said that INO-8875 is an important investigational agent that holds great potential for the treatment of glaucoma and other indications marked by elevated IOP.

“We intend to continue our Phase II programme with INO-8875 in glaucoma in 2010, while also continuing to advance our pipeline which includes novel therapeutic approaches to other serious ophthalmic diseases, including age-related macular degeneration and diabetic retinopathy,” Howes said.

The study was designed to evaluate the safety, tolerability and efficacy of INO-8875 administered topically to the eye.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU